Literature DB >> 19793826

Heavily isotype-dependent protective activities of human antibodies against vaccinia virus extracellular virion antigen B5.

Mohammed Rafii-El-Idrissi Benhnia1, Megan M McCausland, John Laudenslager, Steven W Granger, Sandra Rickert, Lilia Koriazova, Tomoyuki Tahara, Ralph T Kubo, Shinichiro Kato, Shane Crotty.   

Abstract

Antibodies against the extracellular virion (EV or EEV) form of vaccinia virus are an important component of protective immunity in animal models and likely contribute to the protection of immunized humans against poxviruses. Using fully human monoclonal antibodies (MAbs), we now have shown that the protective attributes of the human anti-B5 antibody response to the smallpox vaccine (vaccinia virus) are heavily dependent on effector functions. By switching Fc domains of a single MAb, we have definitively shown that neutralization in vitro--and protection in vivo in a mouse model--by the human anti-B5 immunoglobulin G MAbs is isotype dependent, thereby demonstrating that efficient protection by these antibodies is not simply dependent on binding an appropriate vaccinia virion antigen with high affinity but in fact requires antibody effector function. The complement components C3 and C1q, but not C5, were required for neutralization. We also have demonstrated that human MAbs against B5 can potently direct complement-dependent cytotoxicity of vaccinia virus-infected cells. Each of these results was then extended to the polyclonal human antibody response to the smallpox vaccine. A model is proposed to explain the mechanism of EV neutralization. Altogether these findings enhance our understanding of the central protective activities of smallpox vaccine-elicited antibodies in immunized humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793826      PMCID: PMC2786738          DOI: 10.1128/JVI.01593-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  107 in total

1.  Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.

Authors:  Edward Bell; Mohammad Shamim; J Charles Whitbeck; Georgia Sfyroera; John D Lambris; Stuart N Isaacs
Journal:  Virology       Date:  2004-08-01       Impact factor: 3.616

2.  Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement.

Authors:  Shlomo Lustig; Christiana Fogg; J Charles Whitbeck; Bernard Moss
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

Review 3.  Clinical efficacy of intramuscular vaccinia immune globulin: a literature review.

Authors:  Robert J Hopkins; J Michael Lane
Journal:  Clin Infect Dis       Date:  2004-08-23       Impact factor: 9.079

4.  A prospective study of serum antibody and protection against smallpox.

Authors:  T M Mack; J Noble; D B Thomas
Journal:  Am J Trop Med Hyg       Date:  1972-03       Impact factor: 2.345

5.  Inhibition or enhancement of immunological injury of virus-infected cells.

Authors:  A M Brier; C Wohlenberg; J Rosenthal; M Mage; A L Notkins
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

6.  The morphological and biological effects of various antisera on avian infectious bronchitis virus.

Authors:  D M Berry; J D Almeida
Journal:  J Gen Virol       Date:  1968-07       Impact factor: 3.891

7.  Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.

Authors:  J W Hooper; E Thompson; C Wilhelmsen; M Zimmerman; M Ait Ichou; S E Steffen; C S Schmaljohn; A L Schmaljohn; P B Jahrling
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

9.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

10.  Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.

Authors:  Christiana Fogg; Shlomo Lustig; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more
  35 in total

1.  Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.

Authors:  Megan M McCausland; Mohammed Rafii-El-Idrissi Benhnia; Lindsay Crickard; John Laudenslager; Steven W Granger; Tomoyuki Tahara; Ralph Kubo; Lilia Koriazova; Shinichiro Kato; Shane Crotty
Journal:  Antivir Ther       Date:  2010

2.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

3.  Structural and biochemical characterization of the vaccinia virus envelope protein D8 and its recognition by the antibody LA5.

Authors:  Michael H Matho; Matt Maybeno; Mohammed Rafii-El-Idrissi Benhnia; Danielle Becker; Xiangzhi Meng; Yan Xiang; Shane Crotty; Bjoern Peters; Dirk M Zajonc
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

4.  T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.

Authors:  D Huw Davies; Sookhee Chun; Gary Hermanson; Jo Anne Tucker; Aarti Jain; Rie Nakajima; Jozelyn Pablo; Philip L Felgner; Xiaowu Liang
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

5.  Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8.

Authors:  Michael H Matho; Andrew Schlossman; Iuliia M Gilchuk; Greg Miller; Zbigniew Mikulski; Matthias Hupfer; Jing Wang; Aruna Bitra; Xiangzhi Meng; Yan Xiang; Tom Kaever; Tzanko Doukov; Klaus Ley; Shane Crotty; Bjoern Peters; Linda C Hsieh-Wilson; James E Crowe; Dirk M Zajonc
Journal:  J Biol Chem       Date:  2017-11-09       Impact factor: 5.157

6.  Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Authors:  Elizabeth A Moulton; Paula Bertram; Nanhai Chen; R Mark L Buller; John P Atkinson
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 7.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

Authors:  Yuhong Xiao; Yuhong Zeng; Edward Alexander; Shyam Mehta; Sangeeta B Joshi; George W Buchman; David B Volkin; C Russell Middaugh; Stuart N Isaacs
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

9.  The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.

Authors:  Xueying Ma; Ren-Huan Xu; Felicia Roscoe; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Luis J Sigal
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

10.  Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.

Authors:  Thomas Kaever; Xiangzhi Meng; Michael H Matho; Andrew Schlossman; Sheng Li; Inbal Sela-Culang; Yanay Ofran; Mark Buller; Ryan W Crump; Scott Parker; April Frazier; Shane Crotty; Dirk M Zajonc; Bjoern Peters; Yan Xiang
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.